Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in Diabetic Macular Edema (FORESIGHT)
NCT03780361Phase 4Completed
- Sponsor
- Hyewon Chung
- Start
- May 2019
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in diabetic macular edema (DME), sponsored by Hyewon Chung. Primary endpoint: Soluble CD14 at 20 weeks. Started May 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03780361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780361.